Determining Hepatitis C Drug Resistance Before Prescribing Made Easier

Article

Researchers from Hiroshima University have created a system to detect a drug-resistant viral strain mutation in hepatitis C (HCV) cases.

Researchers from Hiroshima University have created a system to detect a drug-resistant viral strain mutation in hepatitis C (HCV) cases.

The Centers for Disease Control and Prevention (CDC) estimates that 3.2 million Americans are living with chronic HCV. Previous findings indicated that patients with HCV accompanied by a NS5A-Y93H mutation show resistance towards drug treatments. Kazuaki Chayama, MD, PhD, led the development of a fast and effective method to determine the viral strain.

“Several mutations in HCV structural and non-structural proteins have been reported to be associated with interferon resistance, including Core, NS3/NS4A, NS5A, and E2,” the authors wrote in PLOS One.

Viral mutations are often determined using direct sequencing, however, the viral subpopulations cannot drop below 10 to 20%. Next generation sequencing (NGS) methods, such as the Invader assay, are able to detect mutations with a frequency as low as 1%, but it is not a common practice due to the expense and complexity. Chayama and her team developed a wallet-friendly system based off the Invader assay that can sense the NS5A-Y93H drug resistant mutation.

Using 702 serum samples from Japanese patients with HCV genotype 1b, the researchers extracted RNA and evaluated NS5A sequences. The system indicated a 98.9% success rate in determining resistance. The method’s efficiency fell between those of deep-sequencing and direct sequencing.

“Our assay system also showed a much lower detection limit for Y93H than using direct sequencing, and Y93H frequencies obtained by this method correlated well with those of deep-sequencing analysis,” Chayama, a professor at Hiroshima University, said in a news release.

This new assay system was able to work with an Y93H detection limit of about one to 2%. In addition, the system estimated that 23.6% of patients with HCV carry the mutant strain. However, the researchers noted that it was not as sensitive as deep-sequencing.

“The information of NS5A-Y93H strain may provide important information not only for treatment decisions but also for prediction of disease, progression in HCV genotype 1b patients,” the team concluded.

Related Videos
Mitchell Schiffman, MD | Credit: Bon Secours Virginia
Mitchell Shiffman, MD | Credit: Bon Secours
Edward V Loftus, Jr, MD | Credit: Mayo Clinic
Stephen Congly, MD | Credit: University of Calgary
Taha Qazi, MD | Credit: Cleveland Clinic
Taha Qazi, MD | Credit: Cleveland Clinic
Taha Qazi, MD | Credit: Cleveland Clinic
Anthony Lembo, MD | Credit: Cleveland Clinic
Prashant Singh, MD | Credit: University of Michigan
Noa Krugliak Cleveland, MD | Credit: University of Chicago
© 2024 MJH Life Sciences

All rights reserved.